Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1Endocrine 1

Conditions

Pituitary Neoplasms 7Neuroendocrine Tumors 6Carcinoid Tumor 5Acromegaly 5Gastro-enteropancreatic neuroendocrine tumor 3Pituitary ACTH Hypersecretion 2Growth Disorders 2Gigantism 2Serotonin Syndrome 1Prostatic Neoplasms 1Prolactin-Producing Pituitary Tumor 1Pancreatic Neoplasms 1Neuroectodermal Tumors, Primitive 1Neoplasms 1Neoplasm Metastasis 1Nelson Syndrome 1Melanoma 1Lymphoma, Follicular 1Liver Neoplasms 1Insulinoma 1Hypoglycemia 1Hyperinsulinism 1Dumping Syndrome 1Congenital Hyperinsulinism 1Carcinoma, Neuroendocrine 1Carcinoma 1Adrenocortical Hyperfunction 1Adenoma, Islet Cell 1ACTH Syndrome, Ectopic 1

Interventions

Everolimus 2trifluridine tipiracil drug combination 1surufatinib 1pegfilgrastim 1pasireotide 1gallium Ga 68 dotatate 1fosbretabulin 1entinostat 1dactolisib 1belzutifan 1Temozolomide 1TH 302 1Surveys and Questionnaires 1Sunitinib 1Photochemotherapy 1Nivolumab 1Filgrastim 1Fentanyl 1Dihematoporphyrin Ether 190Y-octreotide, DOTA-Tyr(3)- 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neuroectodermal Tumors, Primitive × pasireotide × Endocrine × Clear all
NCT00958841 2016-07-26

Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin

Novartis

Phase 2 Terminated
118 enrolled 11 charts
EndocrineGastrointestinal

ACTH Syndrome, Ectopic, Nelson Syndrome, Pancreatic Neoplasms, Pituitary Neoplasms, Neuroectodermal Tumors, Primitive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡